{"id":"W3216319709","doi":"10.1016/j.ejca.2021.09.043","title":"Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Docetaxel; Medicine; Prostate cancer; Chemotherapy; Oncology; Internal medicine; Nivolumab; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006773623,0.0002246369,0.0004850082,0.00008500021,0.0001511418,0.00007977865,0.0001760184,0.00001884494,0.0002745324],"category_scores_gemma":[0.0001104877,0.0001248279,0.0001255511,0.0003829656,0.0001174214,0.0001815393,0.00004122054,0.0004517694,0.000004899445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004627349,"about_ca_system_score_gemma":0.001679876,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003261118,"about_ca_topic_score_gemma":0.0004063385,"domain_scores_codex":[0.9973905,0.0003842089,0.0007956178,0.0002817879,0.0008079247,0.00033997],"domain_scores_gemma":[0.9981497,0.00008640631,0.0005634629,0.0002948781,0.0007223607,0.0001831753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.802726,0.002618432,0.007301682,0.00009366893,0.002310154,0.004444874,0.01316568,0.0005483106,0.005525874,0.000006891161,0.008488495,0.1527699],"study_design_scores_gemma":[0.8362198,0.009733015,0.1069968,0.001772518,0.0006916541,0.00002580071,0.0009690843,0.00009033138,0.009173597,0.00002517668,0.03395151,0.0003506948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830204,0.006980587,0.00001007071,0.007755016,0.0003579033,0.0007568523,0.0004884921,0.000009230619,0.0006214322],"genre_scores_gemma":[0.9931964,0.002780596,0.0003067337,0.0004222737,0.0005432512,0.00002153787,0.00009091033,0.00005602688,0.002582313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1524192,"threshold_uncertainty_score":0.5090336,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03304210653768105,"score_gpt":0.3307903809683758,"score_spread":0.2977482744306947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}